Antibe Therapeutics (TSE:ATE) Trading 13.5% Higher – Time to Buy?

Shares of Antibe Therapeutics Inc. (TSE:ATEGet Free Report) traded up 13.5% during mid-day trading on Monday . The company traded as high as C$0.35 and last traded at C$0.30. 167,044 shares changed hands during mid-day trading, an increase of 23% from the average session volume of 135,475 shares. The stock had previously closed at C$0.26.

Antibe Therapeutics Stock Performance

The firm has a market cap of C$15.64 million, a P/E ratio of -0.84 and a beta of 0.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.58 and a current ratio of 10.06. The company’s 50 day simple moving average is C$0.30.

Antibe Therapeutics Company Profile

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

See Also

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.